No results found for this search.
In an increasingly global society, collaboration and knowledge-sharing between countries offer opportunities for expedited and cost-effective advancements in the medical and biotech fields. At the same time, creating global devices...
The opioid epidemic is a pressing public health crisis. Opioid overdoses have become the leading cause of accidental death, surpassing automobile accidents. This crisis has only been exacerbated during the...
Don’t miss the Commonwealth’s flagship event connecting scientific innovators, entrepreneurs, business leaders, and investors to celebrate the many ways Massachusetts leads the nation in bringing translational science to the market!...
If the current pandemic has taught us anything, it is the importance of monitoring not only our own health but the health of our loved ones. It has reiterated the...
Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...
Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...
Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
10:00 – 10:15 AM | Opening by Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies 10:15 – 10:45 AM | Real Time Metabolomics in Biotechnology and Biopharma | Karl Burgess, Senior Lecturer...
Recent history suggests a new vaccine entering human clinical trials has about a 1-in-3 chance of getting FDA approval. Stephane Bancel, chief executive of Moderna, pegs the chances of his company’s novel coronavirus vaccine at closer to 80% to 90%.